source
- Ipsen's Dysport shows positive Phase 3 results in migraine, Tarsus acquires iRenix for $75MIpsen reported that its injectable neurotoxin Dysport met the primary endpoint in a Phase 3 trial aimed at reducing monthly migraine days. The trial demonstrated a statistically significant reduct…
- Prime Secures Arbitration Victory Over Beam, Paving Way for Clinical TrialsPrime, a biotech firm developing a gene‑therapy candidate, won an arbitration case against Beam Therapeutics. The ruling removes a legal hurdle and allows Prime to advance its program into clinical…